FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Giaccia Amato 2. Issuer Name and Ticker or Trading Symbol Aravive, Inc. [ ARAV ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O ARAVIVE, INC., 3730 KIRBY DRIVE, SUITE 1200
3. Date of Earliest Transaction (MM/DD/YYYY)
3/19/2021
(Street)
HOUSTON, TX 77098
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  3/19/2021    M    8055  A $0.06  949935  D   
Common Stock  3/19/2021    M    4028  A $0.06  953963  D   
Common Stock  3/19/2021    G   V 12083 (1) D $0.00  941880  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy)  $0.06  3/19/2021    M        8055   10/12/2018 (2) 4/25/2021  Common Stock  8055  $0.00  0  D   
Stock Option (Right to buy)  $0.06  3/19/2021    M        4028   10/12/2018 (2) 4/25/2021  Common Stock  4028  $0.00  0  D   

Explanation of Responses:
(1)  This transaction involved a gift of securities by the reporting person to The Denise Chan Cancer Biology Program Endowed Fund in the Stanford Cancer Institute in the School of Medicine.
(2)  On April 26, 2011, the reporting person was granted certain options to purchase shares of common stock at an exercise price of $0.02 per share. Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018 (the "Merger Agreement"), these options were converted into options to purchase an aggregate of 12,083 (8,055 and 4,028) shares of common stock (as adjusted a stock split) of Aravive, Inc. at a per share exercise price of $0.06 per share (as adjusted for a stock split). The options were fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger described in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Giaccia Amato
C/O ARAVIVE, INC.
3730 KIRBY DRIVE, SUITE 1200
HOUSTON, TX 77098
X



Signatures
/s/ Abel Svitavsky, Attorney-In-Fact 3/22/2021
**Signature of Reporting Person Date
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Aravive Charts.
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Aravive Charts.